BioSpace News Archive

Financing Accelerates Development of First-in-Class Therapies with Genetically Validated Mechanisms for Treatment of Autoimmune Diseases, Rare Diseases and Cancer

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, announced that Health Canada provided regulatory clearance for Appili’s Phase 2 study evaluating FUJIFILM Toyama Chemical’s favipiravir as a preventative measure against COVID-19 outbreaks.

End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis Suppurativa Initial promising results reported in Pyoderma Gangraenosum Part 1 of adaptive randomized trial in severe COVID-19 pneumonia fully enrolled Signed clinical collaboration agreement in oncology Cash, cash equivalents and financial assets of approximately €108.0 million as of March 31, 2020 JENA, Germany, May 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage

Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (“Auxly” or the “Company”) has issued an additional $2 million worth of unsecured convertible debentures (collectively, the “Second Tranche”) under its $25 million unsecured convertible debenture standby facility with an institutional investor (the “Investor”) as previously announced on April 28, 2020 (the “Original Offering”).

Alcami, a North Carolina-based contract development and manufacturing organization, announced further additions to strengthen its senior leadership team.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2020 on Thursday, May 28, 2020. A presentation on the Company’s first quarter 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSye

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of two oral abstract presentations at the upcoming European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress being held virtually from June 6 to 8, 2020. The following virtual oral abstract presentations will be available starti

Phenomenex, Inc., a global leader in the research, design and manufacture of advanced technologies for the separation sciences, introduces the bioZen™ 2.6 µm WidePore C4 core-shell LC column to the existing portfolio of bioZen biological workflow products for the reversed phase analysis of intact and subunit monoclonal antibodies

Incyte announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 8:00 a.m. ET.

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that multiple case series and studies will be presented at the Annual European Congress of Rheumatology (EULAR 2020), being held virtually June 3 - 6, 2020. Several presentations of clinical trial data and in-practice cases will provide results on KRYSTEXXA